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RNA granuleManyproteins exhibit propensities to formﬁbrillar aggregates called amyloids that are rich inβ-sheet structures.
Abnormal accumulation of amyloids in the brain and spinal cords iswell known as amajor pathological change in
neurodegenerative diseases; therefore, amyloids have long been considered as disease culprits formed via pro-
tein misfolding and should be avoided in healthy cells. Recently, however, increasing numbers of proteins
have been identiﬁed that require formation of ﬁbrillar states for exertion of their physiological functions, and
the critical roles of such functional amyloids include amolecular switch for environmental adaptation, a structural
template for catalysis, and a regulator of intracellular signaling. Protein amyloidswill, therefore, bemoreprevailed
in our physiologies thanwe have expected so far. Here, we have reviewed recent studies on such regulatory roles
of protein ﬁbrillar aggregates in various physiologies and further discussed possible relations of functional to
pathological amyloids.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Aproteinmolecule folds into its ownunique structure for expressing
physiological functions. This protein folding has been considered to
proceed solely based upon the information coded in a primary sequence
of amino acids, which is known as Anﬁnsen's dogma [1]. A natively
folded state of a protein, nonetheless, is always in equilibrium with
less-populated, non-nativemisfolded states [2]. Usually, we have elabo-
rate, multiple systems that can degrade and recycle those misfolded
proteins (for example, [3]), but once such a quality control of proteins
is somehow impaired, abnormal proteinswithmisfolded conformations
accumulate inside andoutside cells and are considered to exhibit poten-
tially toxic properties [4]. Protein misfolding has been thus extensively
discussed in relation to several human diseases, amongwhich neurode-
generative diseases particularly draw attention to many researchers.
Neurodegenerative diseases are the ones that associate with degen-
eration of neurons, and in many cases, abnormal accumulation of
misfolded proteins can be observed as one of the major pathological
changes in the brains and spinal cords [5,6]. While distinct sets of pro-
teins have been known to misfold among different neurodegenerative
diseases, those misfolded proteins commonly form insoluble ﬁbrillar
aggregates with cross-β-sheet structures [7]. Cross-β-sheet motif iskohama, Kanagawa 223-8522,
okyo 113-8421, Japan. Fax:+81
ukawa),
rights reserved.composed of intermolecular β-sheets along the ﬁbril axis with the
β-strands aligned perpendicularly to the ﬁbril axis [8,9]. Given that
themain chain of a constituent protein forms a basic scaffold of ﬁbrillar
aggregates, protein ﬁbrillation is considered to be one of innate proper-
ties common to all proteins [10]. If so, all proteins may be potentially
toxic upon misfolding to their ﬁbrillar conformations. Various proteins
have been indeed identiﬁed as being pathogenic/pathological upon
their aggregation [11], and even a protein that is not involved in any
of the misfolding diseases appears to become cytotoxic by forcing it
into aggregation [12].
Actually, it still remains controversial whether protein aggregation
is really detrimental to our physiologies, and ﬁbrillar aggregation of
proteins may even protect cells from potentially toxic protein con-
formers [13,14]. Furthermore, it is also reasonable to assume that nature
will take advantage of such aggregating properties of proteins for regu-
lation of some physiological processes; indeed, increasing numbers of
recent studies have supported this idea on positive functions of protein
ﬁbrils/aggregates. In this review, we will hence brieﬂy summarize
recent studies on physiologically functional as well as pathological as-
pects of protein ﬁbrillar aggregates.
2. Fibrillar aggregates in neurodegenerative diseases
Protein ﬁbrils with cross-β-sheet structures exhibit an X-ray diffrac-
tion signature known as the cross-β pattern with a meridional reﬂec-
tion at ca. 4.7 Å corresponding to the inter-β-strand spacing and an
equatorial reﬂection at ca. 6–11 Å corresponding to the distance be-
tween stacked β-sheets [8,9]. We have often used a term “amyloid”
for the protein ﬁbrils rich in β-sheets, but its deﬁnition has actually
Table 1
Biophysical methods commonly used to diagnose the amyloid structures in protein
aggregates.
Methods Diagnosis of typical amyloids
X-ray diffraction An X-ray diffraction signature with a meridional
reﬂection at ca. 4.7 Å and an equatorial reﬂection at
ca. 6–11 Å (i.e. cross-β-sheet structures)
Thioﬂavin T/S ﬂuorescence Thioﬂavin T/S becomes ﬂuorescent upon binding to
amyloid, which is detected with ﬂuorimeter and
ﬂuorescence microscope.
Congo red binding Congo redbinds amyloid and then shows apple-green
birefringence under polarized light (microscope). In
addition, a visible spectrum of Congo red is
red-shifted uponbinding to amyloids (spectrometer).
Electron microscopy Typical amyloid is ﬁbrillarwith ca. 10 nmof thewidth.
Circular dichroism (CD) A CD spectrum of amyloid is characterized by a




An IR spectrum of amyloid is characterized by an
amide I band between 1615 and 1640 cm−1,
representing the abundance of β-sheet structures.
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tion of amyloid is an extracellular, proteinaceous deposit; after stained
with Congo red, those deposits show apple-green birefringence under
polarized light [16], and increased intensity of Thioﬂavin S/T ﬂuores-
cence is also characteristic to amyloid deposits [17]. Such classical amy-
loids are then found to be rich in β-sheet structures with ﬁbrillar
morphologies and exhibit the cross-β pattern in their X-ray diffraction
[9]. Given that various proteins turn out to share propensities to form
such ﬁbrillar aggregates, therefore, many researchers have increasingly
referred to protein ﬁbrillar aggregates as amyloids in a broader deﬁni-
tion,which is actually irrelevant towhether the aggregates are extracel-
lular or intracellular and even whether they exhibit the Congo red
birefringence. To avoid confusion in this review, amyloid will be used
almost synonymously with protein ﬁbrillar aggregates rich in β-sheets
(also see Table 1).
The formation of such amyloids has been often observed as a major
pathological change in many neurodegenerative diseases [5,6,11,18].
Alzheimer's disease is characterized by extracellular deposit of
amyloids that are composed of amyloid-β peptides [19], while intra-
cellular amyloids of tau, α-synuclein and polyglutamine proteins are
pathological features of tauopathies [20], α-synucleopathies [21], and
polyglutamine diseases [22], respectively. Many excellent reviews
have been available on structural and biochemical properties of amy-
loids of those pathological proteins [5,6,11,23,24], and we will henceTable 2




SOD1 Human Superoxide dismutase
Prion protein (PrP) Human –b)
Sup35 Yeast Translation terminator
Mod5 Yeast tRNA isopentenyltransferase
CPEB Marine snail Transcriptional activator/repres
Fruit ﬂy
Pmel17 Human Melanin synthesis
RIP1, RIP3 Human Kinases
p62 Human Sequestosome formation
GW182 Human P-body formation
RCK/p54 Human P-body formation
TIA-1 Human Stress granule formation
TDP-43 Human DNA/RNA binding protein
FUS/TLS Human DNA/RNA binding protein
a) ThT, Thioﬂavin T; CR, Congo red; EM, Electron microscopy; X-ray, X-ray diffraction. b) S
controversial.not go into the details here (also see Table 2). In some of the neurode-
generative diseases, nonetheless, it remains controversial whether
pathological aggregates bear amyloid-like characters. For example, mu-
tant Cu,Zn-superoxide dismutase (SOD1) proteins, which are responsi-
ble for a subset of amyotrophic lateral sclerosis (ALS) [25], form Congo
red/Thioﬂavin-T-positive amyloids in vitro [26]; however, neither
Congo red staining with apple-green birefringence nor Thioﬂavin-T
staining with signiﬁcant enhancement of ﬂuorescence has been ob-
served in pathological SOD1-positive inclusions in SOD1-related
ALS patients [27] (Table 1). Actually, these staining methods for am-
yloid diagnosis have not been routinely performed in the tissue sec-
tions from patients with neurodegenerative diseases. The affected
tissues of patients with neurodegeneration, therefore, need to be in-
vestigated in more detail by staining with amyloid-speciﬁc dyes,
which will clarify whether formation of amyloid-like aggregates is
a common pathological change in neurodegenerative diseases.
3. Prions as pathogenic and functional amyloids
Upon formation of amyloids, a protein changes its conformation,
and such a conformational change is usually an uphill process that re-
quires surpassing a high-energy barrier [28]. Once even very small
amounts of initial oligomers form, however, the following growth or
elongation process of amyloid ﬁbrils becomes downhill. Amyloid is
hence considered to assume a self-propagating conformer; that is,
pre-existing amyloids can function as a structural template (or
“seed”) to convert a native conformation of the constituent protein
to the amyloid state [28]. This is called a seeding reaction and is actu-
ally an interesting feature of amyloids that cannot be realized with
the conformations of proteins in their native states.
The most notable example of a seeding reaction can be found in a
molecular description of prion. Prion is a nucleic acid-free proteina-
ceous agent with infectivity [29], the idea of which has been originally
conceived in transmissible neurodegenerative diseases such as the
Creutzfeldt–Jakob disease and bovine spongiform encephalopathy
[30]. In those prion diseases, ﬁbrillar aggregates of human prion pro-
tein (PrP) have been observed as a major pathological change [30];
indeed, PrP forms amyloid-like aggregates in vitro and in vivo, which
further functions as seeds to transmit the pathogenic state among
model animals [31,32]. Also in the other neurodegenerative diseases,
where no infectivity has been deﬁnitely conﬁrmed, a seeding activity
of protein ﬁbrils may describe the propagation of pathological
changes within the affected tissues [33–37]. After being transduced
into cultured cells [38–43] or directly injected into the brain of a
model animal [44–48], ﬁbrillar aggregates prepared from puriﬁedDetection methods for
aggregates (also see Table 1)a)
Aggregated state
Pathological ThT, CR, EM, X-ray, etc.
Pathological ThT, CR, EM
Pathological ThT, CR, EM, X-ray, etc.
Functional ThT, CR, EM, X-ray, etc
Functional ThT, EM
sor Functional ThT, EM
Functional ThT, CR, EM, X-ray




Functional ThT, CR, EM
Pathological/functional? ThT, CR, EM
Pathological/functional? EM
everal physiological roles have been proposed, but their distinct roles have been still
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conformations to endogenously expressed proteins. How such seeding
reactions are involved in a pathomechanism of neurodegenerative
diseases still remains obscure, but a prion may not be conﬁned within
a simple view of toxic and infectiousmaterials. Rather, some physiolog-
ical processes appear to be regulated by prionization of proteins
through their amyloid-like aggregation.
Actually, increasing numbers of studies using the baker's yeast
Saccharomyces cerevisiae have revealed that formation of prions and
thus amyloid-like aggregates is physiologically beneﬁcial under certain
circumstances [49]. The best understood prion protein in yeast is a
translation termination factor, Sup35 [50]. Sup35 has been shown to
form amyloid-like ﬁbrils in vitro [51] and in vivo [52] (Table 2), which
can be accelerated by intracellular overexpression of recombinant
Sup35 [53] or triggered by introducing exogenous Sup35 ﬁbrils into
cells [54]. In yeast, Sup35 amyloids appear to be easily fragmented by
several intracellular factors such asHsp104, and the resulting fragments
are disseminated frommother to daughter cells [55]. A seeding activity
of those fragments maintains Sup35 in the amyloid state in the daugh-
ter cells, and thereby, the [PSI+] phenotype caused by Sup35 amyloids is
epigenetically inherited in many generations. Upon amyloid formation,
Sup35 will totally or partially lose its function as a translation termina-
tor, which instead confers a growth advantage under certain conditions
(e.g. in the presence of paraquat) [56]. Compared to yeast without
aggregated Sup35 ([psi−]), [PSI+] has been also found to display a
greater sensitivity to some chemicals such as hydroxyurea [56]. Accord-
ingly, the changes in gene expression caused by ﬁbrillation of Sup35
have diverse phenotypic effects,whichmay lead to a survival advantage
under certain environmental stresses [56,57].
In addition to Sup35, several other prion proteins have been pro-
posed to control phenotypes by converting their “native” conformations
to ﬁbrillar aggregates, and importantly, such “acquired” phenotypes are
stably inherited in many generations due to the seeding activity of
yeast prions [49]. Recently, Suzuki et al. have added Mod5, a tRNA
isopentenyltransferase, as a growing list of such yeast prion proteins
[58]. Mod5 was shown to form amyloid-like ﬁbrillar aggregates in
vitro and in vivo (Table 2); but, quite interestingly, Mod5 lacks Gln
(Q)/Asn (N)-rich domains. All of the other yeast prion proteins charac-
terized so far are known to possess an aggregation-prone Q/N-rich se-
quence, which is actually critical for the formation of self-propagating
amyloid [59]. In contrast, Mod5 utilizes an aggregation-prone sequence
without a Q/N-rich region for formation of the structural core of
self-propagating amyloid, which then produces the [MOD+] phenotype
with dominant inheritance. A Q/N-rich sequence is thus not absolutely
required for prionogenicity of proteins; rather, more diverse proteins
would be involved in the emergence of distinct but still uncharacterized
prion states upon their amyloid-like aggregation. Physiologically,
furthermore, Mod5 uses dimethylallyl pyrophosphate (DMAPP) as a
substrate for isopentenylation of tRNA, but DMAPP is also a competitive
substrate for the sterol biosynthetic pathway. In the [MOD+] prion
state, therefore, Mod5 becomes dysfunctional due to its ﬁbrillar aggre-
gation, which can increase the supply of DMAPP to synthesize sterols.
Indeed, the formation of Mod5 prions in yeast increases the production
of ergosterol and thereby acquires the resistance to antifungal agents.
Yeast cells may thus adapt to various environmental stresses by
converting certain proteins into the prion state and modulating their
phenotypes.
Prion-like behaviors regulated by amyloid-like aggregation of pro-
teins have been also proposed in the sea snail Aplysia and the fruit ﬂy
Drosophila [60,61]. A translation regulator CPEB of those organisms
forms multimers with amyloid-like properties (Table 2), which has
been proposed to contribute to the persistence of synaptic facilitation.
CPEB is an RNA-binding protein that can act as transcriptional repressor
and activator of its target mRNA, and persistence of synaptic facilitation
requires a continuous synaptic protein synthesis that is mediated by
CPEB. In a naïve synapse, CPEB appears to exist in a monomeric state,which is either inactive or acts as a transcriptional repressor. Upon
neuronal stimulation, CPEB is converted to an amyloid-like multimeric
state that functions as a transcriptional activator. Unlike pathogenic
proteins, CPEB in the amyloid state exhibited no adverse effects on
either synaptic functions or viability of neurons. While it still remains
obscure whether CPEB behaves as a canonical prion protein in Aplysia
and Drosophila, CPEB multimers in neurons appear to continuously
recruit newly synthesized CPEB monomers, supporting its seeding
activity in vivo. A self-sustaining property of amyloid-like aggregates
would thus contribute to the persistence of long-termmemory through
the maintenance of activity-dependent synaptic changes.
A seeding activity of amyloid-like aggregates hence well explains
the behavior of prion and is now found to play regulatory roles in
some of physiological processes. Such functional amyloids exhibiting
prion behavior have not, however, been found in mammals; instead,
all of mammalian prions characterized so far appear to be linked to
pathogenesis. Given that many of prionogenic proteins in yeast and
fungi are involved in transcriptional and/or translational regulation
[49], their conversion to a prion state affords to modulate expression
of many target genes. Also in mammals, it should be noted that some
of transcription/translation factors possess Q/N-rich domains [59];
therefore, those factors may behave as prions by their amyloid-like
aggregation and contribute to the emergence of alternative phenotypes
under certain circumstances.4. Functional amyloids in mammals
As mentioned, most of amyloid-like aggregates are linked to the pa-
thologies of diseases in mammals, but recently several studies have re-
vealed their important roles in physiological processes. Melanin is an
important polymer that can protect against a broad range of cytotoxic
insults including oxidative and UV damages, and amyloid-like aggre-
gates of Pmel17 serve as a structural template for the formation of
melanin polymers in melanosomes [62]. Pmel17 is a transmembrane
glycoprotein, and its lumenal fragment self-assembles into β-sheet-rich
ﬁbrils, which are positive to amyloid-diagnostic dyes, Thioﬂavin-S and
Congo red (Tables 1 and 2). Interestingly, amyloids of Aβ peptides and
α-synuclein can replace the templating functions of Pmel17 amyloids
for melanin synthesis, suggesting physiological roles of cross-β-sheet
structures.
Another example of functional amyloids in mammals can be found
in the storage of peptide hormones in secretory granules of the endo-
crine system [63]. Some secretory cells are required to store secretory
proteins/peptides for extended time periods in a highly concentrated
form. For that purpose, very stable structures of amyloid-like aggregates
are well expected to be best suited; indeed, many peptide/protein hor-
mones form amyloid-like aggregates with cross-β-sheet conformations
(Table 1). Notably, amyloids of those peptide/protein hormones are
easily disaggregated upon dilution in vitro, which is quite consistent
with the fact that hormones need to be released as their monomeric
and functional forms upon granule secretion.
Amyloid formation has beenmore recently proposed to play regula-
tory roles in a signal transduction [64]. To initiate a signaling pathway
for cell death known as programmed necrosis, the intracellular kinases,
RIP1 and RIP3, need to be activated and assembled to form necrosome.
Both RIP1 and RIP3 possess unique segments of homologous sequences
(RIP homotypic interaction motifs, RHIMs), through which these two
proteins are found to form a ﬁbrillar complexwith amyloid-like charac-
ters in in vitro and in vivo experimental conditions (Table 2). Formation
of the RIP1/RIP3 amyloid appears to control the expression of their
kinase activity, which is crucial for induction of programmed necrosis.
While it remains unclear how the enzymatic activation is positively
controlled by the formation of amyloid structures, oligomeric scaffold
of amyloids would be useful to bring several different types of signaling
proteins into close proximity and then allow controlling their
1274 Y. Furukawa, N. Nukina / Biochimica et Biophysica Acta 1832 (2013) 1271–1278activation. Indeed, the RHIM sequence can be found in several other
signaling proteins such as the Toll-like receptor signaling adaptor TRIF.
Furthermore, aggregation of proteins, albeit not ﬁbrillar, can be
considered to play regulatory roles in clearance of misfolded proteins.
This may be paradoxical, because protein aggregates have been often
regarded as clogs of misfolded proteins that cannot be correctly
degraded [65]. In a cell, misfolded proteins are tagged with a small pro-
tein, ubiquitin, and then degraded through the ubiquitin–proteasome
system [66,67]. Compensatory to this protein-degradation system,
selective macroautophagy, which is regulated by a protein p62, is also
known to be capable of clearing ubiquitinated proteins [68]. p62 binds
polyubiquitinated proteins through its ubiquitin-associated (UBA) do-
main [69] and has, therefore, been considered to play roles in collecting
polyubiquitinated proteins to form aggregates called sequestosomes
[70]. Unlike amyloid-like aggregates, sequestosomes can be regarded
as amorphous aggregates consisting of heterogeneous mixtures of
polyubiquitinated proteins and allow dynamic molecular exchange be-
tween its inside and the cytoplasm [71]. Sequestosomes function as a
precursor of autophagosomes, where polyubiquitinated proteins are
degraded [72]; in that sense, therefore, sequestosomes can be consid-
ered as functional protein aggregates.
It is notable that the formation of sequestosomes, albeit amorphous,
is not randombutwell regulated by p62.Matsumoto et al. have recently
revealed that the speciﬁc phosphorylation of p62 at Ser403 in the UBA
domain drastically increases its afﬁnity to a polyubiquitin chain and
thereby enables efﬁcient targeting of polyubiquitinated proteins to
sequestosomes [71]. Furthermore, casein kinase 2 (CK2) has been
found to phosphorylate Ser403 of p62 and thus facilitate the formation
of sequestosomes and autophagic degradation of polyubiquitinated
proteins [71]. For example, a mutant form of huntingtin (HTT) protein
has been well known to form ﬁbrillar aggregates and constitutes inclu-
sions inHuntington's disease [22], but enhancingphosphorylation of in-
tracellular p62 by overexpression of CK2 signiﬁcantly reduces the
formation of HTT inclusions in cultured cells [71]. More speciﬁcally, in-
creased fractions of phosphorylated p62 facilitate the recruitment of
polyubiquitinated HTT proteins into sequestosomes, leading to efﬁcient
clearance of intracellular HTT proteins by autophagy. p62 would thus
be a key player to control two distinct pathways of protein aggregation;
i.e. functional sequestosomes or pathological amyloids.
Also in mammals, therefore, protein aggregation is not simply
regarded as a cytotoxic process and/or a pathological outcome; rather,
more signiﬁcance should be emphasized on functional aspects of
amyloid-like or even amorphous conformations than we have ever
expected. Increasing numbers of researchers now thus attempt to look
for physiological signiﬁcance of protein aggregates, and one of those
candidates we have suspected in this review is an RNA granule that
would control both physiological and pathological processes.
5. RNA granules as a new entity of protein functional amyloids
Cytoplasmic RNA granules contain various factors including RNAs,
ribosomal subunits, and RNA-binding proteins, and thereby control
the translation, storage, and degradation of RNAs [73–75]. Processing
bodies (P-bodies) and stress granules are two major RNA granules in
the cytoplasm of somatic cells. P-bodies, which have been considered
as active sites of mRNA degradation, are constitutively present and
visible as cytoplasmic foci by light microscopy in somatic cells [76].
Because many proteins have been identiﬁed as constituents of
P-bodies [76], their formation appears not to be regulated dominantly
by a single protein but is considered as a highly cooperative process.
Interestingly, sequence analysis of twenty protein components of
P-bodies in yeast has revealed that those proteins commonly possess
Q/N-rich regions of varying lengths [77]. As exempliﬁed in polyQ pro-
teins and yeast prion proteins, Q/N-rich sequences are well known to
exhibit high propensities for the formation of ﬁbrillar aggregates [59].
Q/N-rich proteins in yeast P-bodies are thus considered to adopt theamyloid-like ﬁbrillar conformation (Table 1) and may even exhibit
prion-like behaviors. The Q/N-rich sequences of those yeast P-body
proteins are, however, not conserved in the human homologues,
suggesting an alternative mechanism of P-body formation in human
[77]. Despite this, P-bodies in human cells appear to comprise of ﬁbrils
of approximately 10 nm in diameter [78,79], which is reminiscent of
amyloid. Such ﬁbrillar structures in P-bodies can be detected with anti-
bodies against GW182 [78] and RCK/p54 [79], both of which have been
used as excellent markers of P-bodies (Table 2). Notably, GW182
possesses anN-terminal low-complexity region rich inQ and P residues,
and RCK/p54 is also equippedwith anN-terminal sequence slightly rich
in Q and N residues. It is thus tempting to speculate that amyloids of
GW182 and RCK/p54would be functional so as to control the formation
of P-bodies.
Unlike P-bodies, the other RNA granules, i.e. stress granules, appear
only during environmental stresses such as oxidative stress, heat
shock and UV irradiation, and after removal of those stresses, stress
granules will immediately disappear [80–82]. Typically, poly(A)+
mRNA, 40S ribosomal subunits and several translation initiation factors
are recruited into stress granules, suggesting their roles in stalling the
process of translation [80–82]. The formation of stress granules plays
important roles in triaging mRNAs for cell survival under stresses, be-
cause a cellular energy could be saved efﬁciently by globally repressing
translation upon the granule formation and used preferentially for
expression of stress-induced transcripts such as chaperones.
Stress granules and P-bodies are known to sometimes function in
concert for controlling the metabolism of intracellular RNAs [76],
while those two granules are distinct in their morphologies and com-
positions. Similar to P-bodies, nonetheless, molecular structures of
stress granules appear to possess structural regularity to some degree.
For example, ultrastructural analysis of arsenite-induced stress granules
in HeLa and HEK293 cells has identiﬁed cytoplasmic ﬁbrillo-granular
aggregates not seen in control unstressed cells [79]. Unlike bona ﬁde
amyloids, stress granules are composed of many proteins and are difﬁ-
cult to be puriﬁed due to their fragility, which hampers accurate identi-
ﬁcation of proteins in stress granules. Nonetheless, TIA-1, an RNA-
binding protein, has been well known as one of the major components
of stress granules [83]. Quite notably, TIA-1 possesses a Q/N/Y/G-rich
sequence at its C-terminal region (TIA-1C), which exhibits some simi-
larity to the prion domain of Sup35 [84]. Indeed, a recombinant
full-length TIA-1 protein is highly prone to aggregation and forms
amyloid-like ﬁbrils in vitro, and TIA-1C constitutes the core structure
of those ﬁbrils [85] (Table 2). Interestingly, overexpression of full-
length TIA-1 has been known to facilitate the assembly of actual revers-
ible stress granules [86]. TIA-1C also forms cytoplasmic aggregates
when ectopically expressed in cultured cells, but those aggregates are
found to be irreversible [84]. Furthermore, TIA-1C aggregates sequester
endogenous full-length TIA-1 proteins and thereby prevent the assem-
bly of inherent stress granules even after environmental stresses [84].
TIA-1 would thus be able to adopt at least two types of aggregate struc-
tures; one is reversible and ﬁbrillo-granular (full-length TIA-1), and the
other is amyloid-like irreversible ﬁbrils (TIA-1C). As suggested previ-
ously, a sub-lethal stress to cells induces the reversible aggregation of
TIA-1 and forms canonical stress granules [83]. When a stress becomes
lethal to cells, however, the intracellular aggregates containing TIA-1
have been proposed to become irreversible that do not disappear
even after removal of stresses [83]. TIA-1 may thus form aggregates
with distinct structures,which can play either functional or pathological
roles (Fig. 1). While no reports have so far supported a genetic link
between TIA-1 and any diseases, TIA-1 proteins have been found to
co-localize with pathological inclusions in neurodegenerative diseases
[85,87–90]. Conversely, several pathogenic and aggregating proteins
in neurodegenerative diseases such as ataxin-2 [91–93], FMRP [94],
and SMN [95] have been identiﬁed as constituents of stress granules
[81]; therefore, a tight link of stress granules (i.e. functional aggregates)
with pathological aggregates has been increasingly noticed.
Fig. 1. Possible roles of stress granules in the formation of amyloid-like aggregates. Upon various types of sub-lethal stresses, TIA-1 is re-localized from nucleus to cytoplasm and
then forms stress granules, which appear to be ﬁbrillar protein aggregates. When such stresses become lethal to the cell, TIA-1 would form alternative ﬁbrillar aggregates that are
irreversibly insoluble. TDP-43 and FUS/TLS possess similar domain organization to that of TIA-1 and are normally localized in nucleus. Upon environmental changes (TDP-43) and
genetic mutations (FUS/TLS), these proteins become cytoplasmic and appear to be reversibly recruited to stress granules. It is nonetheless possible that such stress granules function
as seeds to accelerate the pathological formation of irreversible amyloid-like ﬁbrils of TDP-43 and/or FUS/TLS.
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In 2006, an RNA-binding protein, TDP-43, has been identiﬁed as a
major component of pathological inclusions in amyotrophic lateral
sclerosis (ALS) and frontotemporal lobar degeneration (FTLD)
[96,97], which follows the discoveries of disease-causing mutations
in TDP-43 gene in the familial form of ALS [98–101]. TDP-43 normally
localizes at the nucleus but forms insoluble aggregates at the cytoplasm
under pathogenic conditions [96,97]. In addition to the N-terminal RNA
recognition motifs (RRMs), TDP-43 possesses the low-complexity
sequence at its C-terminal region, which has been proposed to play
key roles in pathological aggregation [40,102]. Notably, the C-terminal
region exhibits sequence similarity to a prion domain of Sup35 and
PrP [103], and, therefore, TDP-43 is quite similar to a stress granule
protein, TIA-1, in the arrangement of primary sequence: i.e. tandem
RRMs followed by a prion domain. As found in TIA-1, indeed, TDP-43
puriﬁed in vitro is also highly prone to formation of amyloid-likeﬁbrillar
aggregates, in which the C-terminal prion domain constitutes a struc-
tural core [40,102] (Table 2). A recent study should be also noted that
pathological inclusions containing TDP-43 in a subset of ALS and FTLD
are actually stained with an amyloid-diagnostic dye, Thioﬂavin S
[104,105] (Table 1).
Given the sequence similarity to that of TIA-1, it is not surprising to
ﬁnd that cytoplasmically mislocalized TDP-43 proteins are recruited
into stress granules upon stresses such as heat shock and oxidative
stress [106]. In addition to the C-terminal prion domain, an N-terminal
RRM1 domain is also required for recruitment of TDP-43 into stress
granules, suggesting that the RNA-binding ability of TDP-43 contributesto the formation of stress granules [106]. An obligatory role of TDP-43 in
the stress granule formation have, however, been questioned by the fact
that wild-type as well as ALS-causing mutant TDP-43 is not recruited
into stress granules with commonly used stressors such as heat shock
[107]; instead, those TDP-43 proteins remain entirely nuclear even
under the stress conditions [106]. As proposed by Pesiridis et al. [108],
two “hits” would be thus required to initiate the pathological aggrega-
tion of TDP-43, in which the ﬁrst hit disturbs the intracellular localiza-
tion of TDP-43. The cause for abnormal redistribution of wild-type and
mutant TDP-43 to the cytoplasm is not clear, but a recent study has
shown that a single traumatic brain injury leads to persistent increases
of cytoplasmic TDP-43 levels [109–111]. Then, continuing stresses
would induce the formation of stress granules, which may serve as
seeds or a second hit to induce the aggregation of cytoplasmic TDP-43
(Fig. 1). In a subset of ALS and FTLD cases, inclusions containing
TDP-43 can be immunostained by anti-TIA-1 antibodies but are found
to be negative to several markers for P-bodies [88]. These observations
have thus supported the speciﬁc convergence of TDP-43 aggregates
and stress granules under pathological conditions.
Increasing attention has been recently paid on roles of RNA granules
in pathological aggregation of proteins by the identiﬁcation of FUS
(fused in sarcoma) as a pathogenic protein for ALS and FTLD [112,113].
FUS/TLS is an RNA-binding protein possessing a prion-like sequence
with low-complexity at its N-terminal region [103] and has been origi-
nally characterized as a part of an oncoprotein fused with the transcrip-
tional factor CHOP due to the chromosomal translocation in liposarcoma
[114,115]. Similar to TDP-43, FUS/TLS is mostly localized in the nucleus
but forms cytoplasmic inclusions under the pathogenic conditions
observed in a subset of ALS and FTLD [112,113]. Pathogenic mutations
1276 Y. Furukawa, N. Nukina / Biochimica et Biophysica Acta 1832 (2013) 1271–1278are mostly concentrated at a C-terminal region of FUS/TLS [116,117],
which compromises the function of a nuclear localization signal at the
C-terminus [118–120] and then facilitates the formation of cytoplasmic
inclusions via unknown mechanisms.
Before the ﬁrst report on FUS/TLS-positive inclusions in ALS, our
grouphas already characterized FUS/TLS as a constituent of pathological
inclusions of polyQ aggregates in Huntington's disease [121], which is
consistent with the intrinsic propensities of FUS/TLS for aggregation. A
Q/S/Y/G-rich prion domain of FUS/TLS at the N-terminal region is re-
quired for its recruitment into polyQ aggregates [121] and also for ag-
gregation of a FUS/TLS protein itself [122]. A recombinant FUS/TLS
protein forms ﬁbrillar aggregates, but those are susceptible to SDS and
also not reactive to amyloid-diagnostic dyes, Thioﬂavin T and Congo
red [122] (Table 1). It remains to be investigated whether FUS/TLS ag-
gregates in pathological inclusions of ALS and FTLD possess amyloid-
like characters, and a recent study has reported no reactivity to
Thioﬂavin S in inclusions of a FTLD patient with FUS/TLS proteinopathy
[105]; however, inmotor neurons of patientswith juvenile ALS, FUS/TLS
has been shown to form ﬁlamentous aggregates with a diameter of
15–20 nm [123,124] (Table 2). Notably, furthermore, neuronal cyto-
plasmic inclusions in patients with FUS/TLS pathology have been
shown to contain the stress granule marker proteins PABP-1 and
eIF4G [119], although normal wild-type FUS/TLS proteins localizing at
nucleus appear not to be involved in the formation of stress granules
even under stress conditions [106,118]. Cytoplasmic mislocalization of
FUS/TLS caused by mutations and/or post-translational modiﬁcations
such as argininemethylation [125] is hence considered as a prerequisite
for its efﬁcient recruitment into stress granules (Fig. 1).
Recently, McKnight and co-workers have discovered that, using cell
or tissue lysates, a biotinylated isoxazole can precipitate various
RNA-binding proteins with signiﬁcant overlap to the constituents of
RNA granules [126,127]. In addition to TIA-1, FUS/TLS appears on their
list of isoxazole-precipitated proteins, many of which contain long
stretches of low-complexity sequence (LC). As mentioned above, an
N-terminal region of FUS/TLS (FUS LC) is rich in Q/S/Y/G and is further
characterized as 27 repeats of the tripeptide sequence [G/S]Y[G/S].
When incubated as a highly concentrated solution (~50 mg/mL),
FUS LC was found to exhibit phase transitioning into a hydrogel-like
state, which is composed of ﬁbrils with 20–30 nm width [127]. Those
FUS LC ﬁbrils produced an X-ray diffraction pattern showing circular
reﬂections at 4.6–4.7 Å and 10 Å, corresponding to the inter-strand
and stacking distances in cross-β-sheet structures, respectively
[127]. Formation of FUS/TLS ﬁbrils constituting hydrogel is inhibited
by phosphorylation of serine residues in a [G/S]Y[G/S]-repeated se-
quence, implying regulatory roles of post-translational processes in ﬁ-
brillation of FUS/TLS [126]. Consistent with the other study reviewed
above [122], SDS treatmentwas found to depolymerize FUS LC hydrogels
into monomers, which suggests some reversibility of FUS/TLS between
its ﬁbrillar and monomeric states in RNA granules. Nonetheless, soluble
FUS LC proteins are efﬁciently recruited into pre-existing hydrogels of
FUS LC [127]. This is reminiscent of the seeding reaction observed in am-
yloids; more interestingly, the hydrogel can further function as seeds to
trigger the recruitment of other LC-containing proteins such as RNPA1
and CIRBP [127]. This “cross-seeding” ability of hydrogels would reﬂect
the fact that various RNA-binding proteins with LC sequence are
trapped in RNA granules. Accordingly, RNA-binding proteins can form
reversible ﬁbrillar aggregates, by which the formation of RNA granules
may be regulated in a cell. Once those aggregates are evolved into irre-
versible amyloid conformations, however, they might behave as being
pathological (Fig. 1).
7. Conclusions
As reviewed above, cross-β-sheet structures of protein assemblies
will be more prevailed in our physiologies than we have expected so
far. Amyloids with such common cross-β-sheet structures, furthermore,appear to be able to make their properties such as reversibility and
cross-seeding activities adapted to their physiological functions. In
other words, a protein is considered to adopt several types of amyloid-
like aggregates with distinct conformations and properties, the balance
among which is critically kept in healthy cells; genetic mutations,
post-translational modiﬁcations, and environmental changes will disturb
such balance and can thereby facilitate the transformation of amyloids
from functional to pathological conformers. Most of pathological amy-
loids are highly insoluble and accumulate in cells to a signiﬁcant extent,
which thus allows identiﬁcation of their constituent proteins. In con-
trast, it will be of extreme difﬁculty to experimentally identify proteins
forming reversible amyloids with small amounts in cells. Based upon
examples of functional amyloids in this review, insoluble amyloids
identiﬁed as pathological changes might correspond to the tip of the
iceberg [128]; instead, we are now moving on to further identiﬁcation
of fragile, reversible amyloids with certain functions, which would oc-
cupy the iceberg below water.Acknowledgements
This work was supported by Grants-in-Aid 24111542 (to Y. F.),
22110004 (to N. N.) for Scientiﬁc Research on Innovative Areas,
24657093 for Challenging Exploratory Research (to Y. F.), 22240037
for Scientiﬁc Research (A) (to N. N.), and Strategic Research Program
for Brain Sciences (to N. N.) from the Ministry of Education, Culture,
Sports, Science and Technology of Japan, CREST from Japan Science
and Technology Agency (to N. N.), a Grant-in-Aid from the Research
Committee for Ataxic Diseases from MHLW (to N. N.), and a grant
from the Takeda Science Foundation (to Y. F.).References
[1] C.B. Anﬁnsen, Principles that govern the folding of protein chains, Science 181
(1973) 223–230.
[2] C.M. Dobson, Protein folding and misfolding, Nature 426 (2003) 884–890.
[3] A.L. Goldberg, Protein degradation and protection against misfolded or damaged
proteins, Nature 426 (2003) 895–899.
[4] R.I. Morimoto, Proteotoxic stress and inducible chaperone networks in neurode-
generative disease and aging, Genes Dev. 22 (2008) 1427–1438.
[5] C.A. Ross, M.A. Poirier, Protein aggregation and neurodegenerative disease, Nat.
Med. 10 (Suppl.) (2004) S10–S17.
[6] C. Soto, Unfolding the role of protein misfolding in neurodegenerative diseases,
Nat. Rev. Neurosci. 4 (2003) 49–60.
[7] R. Nelson,M.R. Sawaya,M. Balbirnie, A.O.Madsen, C. Riekel, R. Grothe, D. Eisenberg,
Structure of the cross-beta spine of amyloid-like ﬁbrils, Nature 435 (2005)
773–778.
[8] A.J. Geddes, K.D. Parker, E.D. Atkins, E. Beighton, “Cross-beta” conformation in
proteins, J. Mol. Biol. 32 (1968) 343–358.
[9] M. Sunde, C. Blake, The structure of amyloid ﬁbrils by electron microscopy and
X-ray diffraction, Adv. Protein Chem. 50 (1997) 123–159.
[10] C.M. Dobson, Protein misfolding, evolution and disease, Trends Biochem. Sci. 24
(1999) 329–332.
[11] F. Chiti, C.M. Dobson, Protein misfolding, functional amyloid, and human disease,
Annu. Rev. Biochem. 75 (2006) 333–366.
[12] M. Bucciantini, E. Giannoni, F. Chiti, F. Baroni, L. Formigli, J. Zurdo, N. Taddei, G.
Ramponi, C.M. Dobson, M. Stefani, Inherent toxicity of aggregates implies a
commonmechanism for protein misfolding diseases, Nature 416 (2002) 507–511.
[13] K.F. Winklhofer, J. Tatzelt, C. Haass, The two faces of protein misfolding: gain- and
loss-of-function in neurodegenerative diseases, EMBO J. 27 (2008) 336–349.
[14] S. Treusch,D.M. Cyr, S. Lindquist, Amyloid deposits: protection against toxic protein
species? Cell Cycle 8 (2009) 1668–1674.
[15] J.D. Sipe, A.S. Cohen, Review: history of the amyloid ﬁbril, J. Struct. Biol. 130
(2000) 88–98.
[16] H.P. Missmahl, M. Hartwig, Optical polarization studies of amyloid substance,
Virchows Arch. 324 (1953) 489–508.
[17] J.H. Cooper, A n evaluation of current methods for the diagnostic histochemistry
of amyloid, J. Clin. Pathol. 22 (1969) 410–413.
[18] P. Westermark, Aspects on human amyloid forms and their ﬁbril polypeptides,
FEBS J. 272 (2005) 5942–5949.
[19] R.J. O'Brien, P.C. Wong, Amyloid precursor protein processing and Alzheimer's
disease, Annu. Rev. Neurosci. 34 (2011) 185–204.
[20] V.M. Lee, M. Goedert, J.Q. Trojanowski, Neurodegenerative tauopathies, Annu.
Rev. Neurosci. 24 (2001) 1121–1159.
[21] M. Goedert, Alpha-synuclein and neurodegenerative diseases, Nat. Rev. Neurosci. 2
(2001) 492–501.
1277Y. Furukawa, N. Nukina / Biochimica et Biophysica Acta 1832 (2013) 1271–1278[22] H.Y. Zoghbi, H.T. Orr, Glutamine repeats and neurodegeneration, Annu. Rev.
Neurosci. 23 (2000) 217–247.
[23] A. Aguzzi, T. O'Connor, Protein aggregation diseases: pathogenicity and thera-
peutic perspectives, Nat. Rev. Drug Discov. 9 (2010) 237–248.
[24] F. Chiti, C.M. Dobson, Amyloid formation by globular proteins under native
conditions, Nat. Chem. Biol. 5 (2009) 15–22.
[25] D.R. Rosen, T. Siddique, D. Patterson, D.A. Figlewicz, P. Sapp, A. Hentati, D.
Donaldson, J. Goto, J.P. O'Regan, H.X. Deng, et al., Mutations in Cu/Zn superoxide
dismutase gene are associated with familial amyotrophic lateral sclerosis,
Nature 362 (1993) 59–62.
[26] Y. Furukawa, K. Kaneko, K. Yamanaka, T.V. O'Halloran, N. Nukina, Complete loss
of post-translational modiﬁcations triggers ﬁbrillar aggregation of SOD1 in
familial form of ALS, J. Biol. Chem. 283 (2008) 24167–24176.
[27] A. Kerman, H.N. Liu, S. Croul, J. Bilbao, E. Rogaeva, L. Zinman, J. Robertson, A.
Chakrabartty, Amyotrophic lateral sclerosis is a non-amyloid disease in which
extensive misfolding of SOD1 is unique to the familial form, Acta Neuropathol.
119 (2010) 335–344.
[28] J.D. Harper, P.T. Lansbury Jr., Models of amyloid seeding in Alzheimer's disease
and scrapie: mechanistic truths and physiological consequences of the
time-dependent solubility of amyloid proteins, Annu. Rev. Biochem. 66 (1997)
385–407.
[29] S.B. Prusiner, Novel proteinaceous infectious particles cause scrapie, Science 216
(1982) 136–144.
[30] A. Aguzzi, C. Sigurdson, M. Heikenwaelder, Molecular mechanisms of prion
pathogenesis, Annu. Rev. Pathol. 3 (2008) 11–40.
[31] J. Castilla, P. Saa, C. Hetz, C. Soto, In vitro generation of infectious scrapie prions,
Cell 121 (2005) 195–206.
[32] F. Wang, X. Wang, C.G. Yuan, J. Ma, Generating a prion with bacterially
expressed recombinant prion protein, Science 327 (2010) 1132–1135.
[33] A. Aguzzi, L. Rajendran, The transcellular spread of cytosolic amyloids, prions,
and prionoids, Neuron 64 (2009) 783–790.
[34] P. Brundin, R. Melki, R. Kopito, Prion-like transmission of protein aggregates in
neurodegenerative diseases, Nat. Rev. Mol. Cell Biol. 11 (2010) 301–307.
[35] M. Jucker, L.C. Walker, Pathogenic protein seeding in Alzheimer disease and
other neurodegenerative disorders, Ann. Neurol. 70 (2011) 532–540.
[36] M. Polymenidou, D.W. Cleveland, The seeds of neurodegeneration: prion-like
spreading in ALS, Cell 147 (2011) 498–508.
[37] C. Soto, Transmissible proteins: expanding the prion heresy, Cell 149 (2012)
968–977.
[38] P. Desplats, H.J. Lee, E.J. Bae, C. Patrick, E. Rockenstein, L. Crews, B. Spencer, E.
Masliah, S.J. Lee, Inclusion formation and neuronal cell death through neuron-to-
neuron transmission of alpha-synuclein, Proc. Natl. Acad. Sci. U. S. A. 106 (2009)
13010–13015.
[39] B. Frost, R.L. Jacks, M.I. Diamond, Propagation of tau misfolding from the outside
to the inside of a cell, J. Biol. Chem. 284 (2009) 12845–12852.
[40] Y. Furukawa, K. Kaneko, S. Watanabe, K. Yamanaka, N. Nukina, A seeding reac-
tion recapitulates intracellular formation of Sarkosyl-insoluble transactivation
response element (TAR) DNA-binding protein-43 inclusions, J. Biol. Chem. 286
(2011) 18664–18672.
[41] K.C. Luk, C. Song, P. O'Brien, A. Stieber, J.R. Branch, K.R. Brunden, J.Q.
Trojanowski, V.M. Lee, Exogenous alpha-synuclein ﬁbrils seed the formation of
Lewy body-like intracellular inclusions in cultured cells, Proc. Natl. Acad. Sci.
U. S. A. 106 (2009) 20051–20056.
[42] T. Nonaka, S.T. Watanabe, T. Iwatsubo, M. Hasegawa, Seeded aggregation and
toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative
diseases, J. Biol. Chem. 285 (2010) 34885–34898.
[43] P.H. Ren, J.E. Lauckner, I. Kachirskaia, J.E. Heuser, R. Melki, R.R. Kopito, Cytoplas-
mic penetration and persistent infection of mammalian cells by polyglutamine
aggregates, Nat. Cell Biol. 11 (2009) 219–225.
[44] F. Clavaguera, T. Bolmont, R.A. Crowther, D. Abramowski, S. Frank, A. Probst, G.
Fraser, A.K. Stalder, M. Beibel, M. Staufenbiel, M. Jucker, M. Goedert, M. Tolnay,
Transmission and spreading of tauopathy in transgenic mouse brain, Nat. Cell
Biol. 11 (2009) 909–913.
[45] K.C. Luk, V. Kehm, J. Carroll, B. Zhang, P. O'Brien, J.Q. Trojanowski, V.M. Lee, Patho-
logical alpha-synuclein transmission initiates Parkinson-like neurodegeneration in
nontransgenic mice, Science 338 (2012) 949–953.
[46] M. Meyer-Luehmann, J. Coomaraswamy, T. Bolmont, S. Kaeser, C. Schaefer, E.
Kilger, A. Neuenschwander, D. Abramowski, P. Frey, A.L. Jaton, J.M. Vigouret, P.
Paganetti, D.M. Walsh, P.M. Mathews, J. Ghiso, M. Staufenbiel, L.C. Walker, M.
Jucker, Exogenous induction of cerebral beta-amyloidogenesis is governed by
agent and host, Science 313 (2006) 1781–1784.
[47] Y. Nekooki-Machida, M. Kurosawa, N. Nukina, K. Ito, T. Oda, M. Tanaka, Distinct
conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different
cytotoxicity, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 9679–9684.
[48] H.F. Baker, R.M. Ridley, L.W. Duchen, T.J. Crow, C.J. Bruton, Induction of beta
(A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate.
Comparison with transmission of spongiform encephalopathy, Mol. Neurobiol. 8
(1994) 25–39.
[49] R. Halfmann, S. Lindquist, Epigenetics in the extreme: prions and the inheritance
of environmentally acquired traits, Science 330 (2010) 629–632.
[50] Y.O. Chernoff, A.P. Galkin, E. Lewitin, T.A. Chernova, G.P. Newnam, S.M. Belenkiy,
Evolutionary conservation of prion-forming abilities of the yeast Sup35 protein,
Mol. Microbiol. 35 (2000) 865–876.
[51] J.R. Glover, A.S. Kowal, E.C. Schirmer, M.M. Patino, J.J. Liu, S. Lindquist, Self-seeded
ﬁbers formed by Sup35, the protein determinant of [PSI+], a heritable prion-like
factor of S. cerevisiae, Cell 89 (1997) 811–819.[52] S. Kawai-Noma, C.G. Pack, T. Kojidani, H. Asakawa, Y. Hiraoka, M. Kinjo, T.
Haraguchi, H. Taguchi, A. Hirata, In vivo evidence for the ﬁbrillar structures of
Sup35 prions in yeast cells, J. Cell Biol. 190 (2010) 223–231.
[53] P. Zhou, I.L. Derkatch, S.W. Liebman, The relationship between visible intracellu-
lar aggregates that appear after overexpression of Sup35 and the yeast
prion-like elements [PSI(+)] and [PIN(+)], Mol. Microbiol. 39 (2001) 37–46.
[54] M. Tanaka, P. Chien, N. Naber, R. Cooke, J.S.Weissman, Conformational variations in
an infectious protein determine prion strain differences, Nature 428 (2004)
323–328.
[55] M. Tanaka, P. Chien, K. Yonekura, J.S. Weissman, Mechanism of cross-species
prion transmission: an infectious conformation compatible with two highly
divergent yeast prion proteins, Cell 121 (2005) 49–62.
[56] H.L. True, I. Berlin, S.L. Lindquist, Epigenetic regulation of translation reveals hidden
genetic variation to produce complex traits, Nature 431 (2004) 184–187.
[57] R. Halfmann, D.F. Jarosz, S.K. Jones, A. Chang, A.K. Lancaster, S. Lindquist, Prions
are a common mechanism for phenotypic inheritance in wild yeasts, Nature 482
(2012) 363–368.
[58] G. Suzuki, N. Shimazu, M. Tanaka, A yeast prion, Mod5, promotes acquired drug
resistance and cell survival under environmental stress, Science 336 (2012)
355–359.
[59] M.D. Michelitsch, J.S. Weissman, A census of glutamine/asparagine-rich regions:
implications for their conserved function and the prediction of novel prions,
Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 11910–11915.
[60] A. Majumdar, W.C. Cesario, E. White-Grindley, H. Jiang, F. Ren, M.R. Khan, L. Li,
E.M. Choi, K. Kannan, F. Guo, J. Unruh, B. Slaughter, K. Si, Critical role of
amyloid-like oligomers of Drosophila Orb2 in the persistence of memory, Cell
148 (2012) 515–529.
[61] K. Si, Y.B. Choi, E.White-Grindley, A.Majumdar, E.R. Kandel, Aplysia CPEB can form
prion-like multimers in sensory neurons that contribute to long-term facilitation,
Cell 140 (2010) 421–435.
[62] D.M. Fowler, A.V. Koulov, C. Alory-Jost, M.S. Marks, W.E. Balch, J.W. Kelly, Func-
tional amyloid formation within mammalian tissue, PLoS Biol. 4 (2006) e6.
[63] S.K. Maji, M.H. Perrin, M.R. Sawaya, S. Jessberger, K. Vadodaria, R.A. Rissman, P.S.
Singru, K.P. Nilsson, R. Simon, D. Schubert, D. Eisenberg, J. Rivier, P. Sawchenko,
W. Vale, R. Riek, Functional amyloids as natural storage of peptide hormones in
pituitary secretory granules, Science 325 (2009) 328–332.
[64] J. Li, T. McQuade, A.B. Siemer, J. Napetschnig, K. Moriwaki, Y.S. Hsiao, E. Damko,
D. Moquin, T. Walz, A. McDermott, F.K. Chan, H. Wu, The RIP1/RIP3 necrosome
forms a functional amyloid signaling complex required for programmed necro-
sis, Cell 150 (2012) 339–350.
[65] T. Grune, T. Jung, K. Merker, K.J. Davies, Decreased proteolysis caused by protein
aggregates, inclusion bodies, plaques, lipofuscin, ceroid, and ‘aggresomes’ during
oxidative stress, aging, and disease, Int. J. Biochem. Cell Biol. 36 (2004) 2519–2530.
[66] S. Murata, H. Yashiroda, K. Tanaka, Molecular mechanisms of proteasome
assembly, Nat. Rev. Mol. Cell Biol. 10 (2009) 104–115.
[67] S. Elsasser, D. Finley, Delivery of ubiquitinated substrates to protein-unfolding
machines, Nat. Cell Biol. 7 (2005) 742–749.
[68] M. Komatsu, S. Waguri, M. Koike, Y.S. Sou, T. Ueno, T. Hara, N. Mizushima, J.
Iwata, J. Ezaki, S. Murata, J. Hamazaki, Y. Nishito, S. Iemura, T. Natsume, T.
Yanagawa, J. Uwayama, E. Warabi, H. Yoshida, T. Ishii, A. Kobayashi, M.
Yamamoto, Z. Yue, Y. Uchiyama, E. Kominami, K. Tanaka, Homeostatic levels of
p62 control cytoplasmic inclusion body formation in autophagy-deﬁcient
mice, Cell 131 (2007) 1149–1163.
[69] V. Kirkin, D.G.McEwan, I. Novak, I. Dikic, A role for ubiquitin in selective autophagy,
Mol. Cell 34 (2009) 259–269.
[70] J. Shin, P62 and the sequestosome, a novel mechanism for protein metabolism,
Arch. Pharm. Res. 21 (1998) 629–633.
[71] G. Matsumoto, K.Wada, M. Okuno, M. Kurosawa, N. Nukina, Serine 403 phosphor-
ylation of p62/SQSTM1 regulates selective autophagic clearance of ubiquitinated
proteins, Mol. Cell 44 (2011) 279–289.
[72] D.C. Rubinsztein, T. Shpilka, Z. Elazar, Mechanisms of autophagosome biogenesis,
Current biology: CB 22 (2012) R29–R34.
[73] P. Anderson, N. Kedersha, RNA granules: post-transcriptional and epigenetic
modulators of gene expression, Nat. Rev. Mol. Cell Biol. 10 (2009) 430–436.
[74] P. Anderson, N. Kedersha, RNA granules, J. Cell Biol. 172 (2006) 803–808.
[75] N. Kedersha, P. Anderson, Mammalian stress granules and processing bodies,
Methods Enzymol. 431 (2007) 61–81.
[76] R. Parker, U. Sheth, P bodies and the control of mRNA translation and degradation,
Mol. Cell 25 (2007) 635–646.
[77] M.A. Reijns, R.D. Alexander, M.P. Spiller, J.D. Beggs, A role for Q/N-rich
aggregation-prone regions in P-body localization, J. Cell Sci. 121 (2008) 2463–2472.
[78] Z. Yang, A. Jakymiw, M.R. Wood, T. Eystathioy, R.L. Rubin, M.J. Fritzler, E.K. Chan,
GW182 is critical for the stability of GW bodies expressed during the cell cycle
and cell proliferation, J. Cell Sci. 117 (2004) 5567–5578.
[79] S. Souquere, S. Mollet, M. Kress, F. Dautry, G. Pierron, D. Weil, Unravelling the
ultrastructure of stress granules and associated P-bodies in human cells, J. Cell
Sci. 122 (2009) 3619–3626.
[80] N. Kedersha, P. Anderson, Stress granules: sites of mRNA triage that regulate
mRNA stability and translatability, Biochem. Soc. Trans. 30 (2002) 963–969.
[81] P. Anderson, N. Kedersha, Stress granules: the Tao of RNA triage, Trends
Biochem. Sci. 33 (2008) 141–150.
[82] J.R. Buchan, R. Parker, Eukaryotic stress granules: the ins and outs of translation,
Mol. Cell 36 (2009) 932–941.
[83] N.L. Kedersha, M. Gupta, W. Li, I. Miller, P. Anderson, RNA-binding proteins TIA-1
and TIAR link the phosphorylation of eIF-2 alpha to the assembly of mammalian
stress granules, J. Cell Biol. 147 (1999) 1431–1442.
1278 Y. Furukawa, N. Nukina / Biochimica et Biophysica Acta 1832 (2013) 1271–1278[84] N. Gilks, N. Kedersha, M. Ayodele, L. Shen, G. Stoecklin, L.M. Dember, P.
Anderson, Stress granule assembly is mediated by prion-like aggregation of
TIA-1, Mol. Biol. Cell 15 (2004) 5383–5398.
[85] Y. Furukawa, K. Kaneko, G. Matsumoto, M. Kurosawa, N. Nukina, Cross-seeding
ﬁbrillation of Q/N-rich proteins offers new pathomechanism of polyglutamine
diseases, J. Neurosci. 29 (2009) 5153–5162.
[86] N. Kedersha, M.R. Cho, W. Li, P.W. Yacono, S. Chen, N. Gilks, D.E. Golan, P.
Anderson, Dynamic shuttling of TIA-1 accompanies the recruitment of mRNA
to mammalian stress granules, J. Cell Biol. 151 (2000) 1257–1268.
[87] K. Fujita, H. Ito, S. Nakano, Y. Kinoshita, R. Wate, H. Kusaka, Immunohisto-
chemical identiﬁcation of messenger RNA-related proteins in basophilic inclu-
sions of adult-onset atypical motor neuron disease, Acta Neuropathol. 116
(2008) 439–445.
[88] L. Liu-Yesucevitz, A. Bilgutay, Y.J. Zhang, T. Vanderweyde, A. Citro, T. Mehta, N.
Zaarur, A. McKee, R. Bowser, M. Sherman, L. Petrucelli, B. Wolozin, Tar DNA
binding protein-43 (TDP-43) associates with stress granules: analysis of
cultured cells and pathological brain tissue, PLoS One 5 (2010) e13250.
[89] T. Vanderweyde, H. Yu, M. Varnum, L. Liu-Yesucevitz, A. Citro, T. Ikezu, K. Duff, B.
Wolozin, Contrasting pathology of the stress granule proteins TIA-1 and G3BP in
tauopathies, J. Neurosci. 32 (2012) 8270–8283.
[90] K. Volkening, C. Leystra-Lantz, W. Yang, H. Jaffee, M.J. Strong, Tar DNA binding
protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc superoxide
dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for
altered RNA processing in amyotrophic lateral sclerosis (ALS), Brain Res. 1305
(2009) 168–182.
[91] G. Imbert, F. Saudou, G. Yvert, D. Devys, Y. Trottier, J.M. Garnier, C. Weber, J.L.
Mandel, G. Cancel, N. Abbas, A. Durr, O. Didierjean, G. Stevanin, Y. Agid, A. Brice,
Cloning of the gene for spinocerebellar ataxia 2 reveals a locuswith high sensitivity
to expanded CAG/glutamine repeats, Nat. Genet. 14 (1996) 285–291.
[92] S.M. Pulst, A. Nechiporuk, T. Nechiporuk, S. Gispert, X.N. Chen, I. Lopes-Cendes, S.
Pearlman, S. Starkman, G. Orozco-Diaz, A. Lunkes, P. DeJong, G.A. Rouleau, G.
Auburger, J.R. Korenberg, C. Figueroa, S. Sahba, Moderate expansion of a normal-
ly biallelic trinucleotide repeat in spinocerebellar ataxia type 2, Nat. Genet. 14
(1996) 269–276.
[93] K. Sanpei, H. Takano, S. Igarashi, T. Sato, M. Oyake, H. Sasaki, A. Wakisaka, K.
Tashiro, Y. Ishida, T. Ikeuchi, R. Koide, M. Saito, A. Sato, T. Tanaka, S. Hanyu, Y.
Takiyama, M. Nishizawa, N. Shimizu, Y. Nomura, M. Segawa, K. Iwabuchi, I.
Eguchi, H. Tanaka, H. Takahashi, S. Tsuji, Identiﬁcation of the spinocerebellar
ataxia type 2 gene using a direct identiﬁcation of repeat expansion and cloning
technique, DIRECT, Nat. Genet. 14 (1996) 277–284.
[94] A.J. Verkerk, M. Pieretti, J.S. Sutcliffe, Y.H. Fu, D.P. Kuhl, A. Pizzuti, O. Reiner, S.
Richards, M.F. Victoria, F.P. Zhang, et al., Identiﬁcation of a gene (FMR-1)
containing a CGG repeat coincident with a breakpoint cluster region exhibiting
length variation in fragile X syndrome, Cell 65 (1991) 905–914.
[95] T.G. Thompson, C.J. DiDonato, L.R. Simard, S.E. Ingraham, A.H. Burghes, T.O.
Crawford, C. Rochette, J.R. Mendell, J.J. Wasmuth, A novel cDNA detects homozy-
gousmicrodeletions in greater than 50% of type I spinal muscular atrophy patients,
Nat. Genet. 9 (1995) 56–62.
[96] T. Arai,M. Hasegawa,H. Akiyama, K. Ikeda, T. Nonaka, H.Mori, D.Mann, K. Tsuchiya,
M. Yoshida, Y. Hashizume, T. Oda, TDP-43 is a component of ubiquitin-positive
tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic
lateral sclerosis, Biochem. Biophys. Res. Commun. 351 (2006) 602–611.
[97] M. Neumann, D.M. Sampathu, L.K. Kwong, A.C. Truax, M.C. Micsenyi, T.T. Chou, J.
Bruce, T. Schuck, M. Grossman, C.M. Clark, L.F. McCluskey, B.L. Miller, E. Masliah,
I.R. Mackenzie, H. Feldman, W. Feiden, H.A. Kretzschmar, J.Q. Trojanowski, V.M.
Lee, Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic
lateral sclerosis, Science 314 (2006) 130–133.
[98] M.A. Gitcho, R.H. Baloh, S. Chakraverty, K. Mayo, J.B. Norton, D. Levitch, K.J.
Hatanpaa, C.L. White III, E.H. Bigio, R. Caselli, M. Baker, M.T. Al-Lozi, J.C. Morris,
A. Pestronk, R. Rademakers, A.M. Goate, N.J. Cairns, TDP-43 A315T mutation in
familial motor neuron disease, Ann. Neurol. 63 (2008) 535–538.
[99] E. Kabashi, P.N. Valdmanis, P. Dion, D. Spiegelman, B.J. McConkey, C. Vande
Velde, J.P. Bouchard, L. Lacomblez, K. Pochigaeva, F. Salachas, P.F. Pradat, W.
Camu, V. Meininger, N. Dupre, G.A. Rouleau, TARDBP mutations in individuals
with sporadic and familial amyotrophic lateral sclerosis, Nat. Genet. 40 (2008)
572–574.
[100] J. Sreedharan, I.P. Blair, V.B. Tripathi, X. Hu, C. Vance, B. Rogelj, S. Ackerley, J.C.
Durnall, K.L. Williams, E. Buratti, F. Baralle, J. de Belleroche, J.D. Mitchell, P.N.
Leigh, A. Al-Chalabi, C.C. Miller, G. Nicholson, C.E. Shaw, TDP-43 mutations
in familial and sporadic amyotrophic lateral sclerosis, Science 319 (2008)
1668–1672.
[101] V.M. Van Deerlin, J.B. Leverenz, L.M. Bekris, T.D. Bird, W. Yuan, L.B. Elman, D. Clay,
E.M. Wood, A.S. Chen-Plotkin, M. Martinez-Lage, E. Steinbart, L. McCluskey, M.
Grossman, M. Neumann, I.L. Wu, W.S. Yang, R. Kalb, D.R. Galasko, T.J. Montine,
J.Q. Trojanowski, V.M. Lee, G.D. Schellenberg, C.E. Yu, TARDBP mutations in
amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histo-
pathological analysis, Lancet Neurol. 7 (2008) 409–416.
[102] B.S. Johnson, D. Snead, J.J. Lee, J.M. McCaffery, J. Shorter, A.D. Gitler, TDP-43 is
intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations
accelerate aggregation and increase toxicity, J. Biol. Chem. 284 (2009) 20329–20339.
[103] M. Cushman, B.S. Johnson, O.D. King, A.D. Gitler, J. Shorter, Prion-like disorders:
blurring the divide between transmissibility and infectivity, J. Cell Sci. 123
(2010) 1191–1201.
[104] J.L. Robinson, F. Geser, A. Stieber, M. Umoh, L.K. Kwong, V.M. Van Deerlin, V.M.
Lee, J.Q. Trojanowski, TDP-43 skeins show properties of amyloid in a subset of
ALS cases, Acta Neuropathol. 125 (2013) 121–131.[105] E.H. Bigio, J.Y. Wu, H.X. Deng, E.N. Bit-Ivan, Q. Mao, R. Ganti, M. Peterson, N.
Siddique, C. Geula, T. Siddique, M. Mesulam, Inclusions in frontotemporal lobar
degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral
sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have proper-
ties of amyloid, Acta Neuropathol. 125 (2013) 463–465.
[106] E. Bentmann, M. Neumann, S. Tahirovic, R. Rodde, D. Dormann, C. Haass, Require-
ments for stress granule recruitment of fused in sarcoma (FUS) and TAR
DNA-binding protein of 43 kDa (TDP-43), J. Biol. Chem. 287 (2012) 23079–23094.
[107] C.M. Dewey, B. Cenik, C.F. Sephton, B.A. Johnson, J. Herz, G. Yu, TDP-43 aggregation
in neurodegeneration: are stress granules the key? Brain Res. 1462 (2012) 16–25.
[108] G.S. Pesiridis, K. Tripathy, S. Tanik, J.Q. Trojanowski, V.M. Lee, A “two-hit”
hypothesis for inclusion formation by carboxyl-terminal fragments of TDP-43
protein linked to RNA depletion and impaired microtubule-dependent transport,
J. Biol. Chem. 286 (2011) 18845–18855.
[109] A.C. McKee, B.E. Gavett, R.A. Stern, C.J. Nowinski, R.C. Cantu, N.W. Kowall, D.P.
Perl, E.T. Hedley-Whyte, B. Price, C. Sullivan, P. Morin, H.S. Lee, C.A. Kubilus,
D.H. Daneshvar, M. Wulff, A.E. Budson, TDP-43 proteinopathy and motor neuron
disease in chronic traumatic encephalopathy, J. Neuropathol. Exp. Neurol. 69
(2010) 918–929.
[110] T. Sato, S. Takeuchi, A. Saito, W. Ding, H. Bamba, H. Matsuura, Y. Hisa, I. Tooyama,
M. Urushitani, Axonal ligation induces transient redistribution of TDP-43 in
brainstem motor neurons, Neuroscience 164 (2009) 1565–1578.
[111] V.E. Johnson, W. Stewart, J.Q. Trojanowski, D.H. Smith, Acute and chronically
increased immunoreactivity to phosphorylation-independent but not patholog-
ical TDP-43 after a single traumatic brain injury in humans, Acta Neuropathol.
122 (2011) 715–726.
[112] T.J. Kwiatkowski Jr., D.A. Bosco, A.L. Leclerc, E. Tamrazian, C.R. Vanderburg, C. Russ,
A. Davis, J. Gilchrist, E.J. Kasarskis, T.Munsat, P. Valdmanis, G.A. Rouleau, B.A.Hosler,
P. Cortelli, P.J. de Jong, Y. Yoshinaga, J.L. Haines, M.A. Pericak-Vance, J. Yan, N.
Ticozzi, T. Siddique, D. McKenna-Yasek, P.C. Sapp, H.R. Horvitz, J.E. Landers, R.H.
Brown Jr., Mutations in the FUS/TLS gene on chromosome 16 cause familial
amyotrophic lateral sclerosis, Science 323 (2009) 1205–1208.
[113] C. Vance, B. Rogelj, T. Hortobagyi, K.J. De Vos, A.L. Nishimura, J. Sreedharan, X. Hu, B.
Smith, D. Ruddy, P.Wright, J. Ganesalingam, K.L.Williams, V. Tripathi, S. Al-Saraj, A.
Al-Chalabi, P.N. Leigh, I.P. Blair, G. Nicholson, J. de Belleroche, J.M. Gallo, C.C. Miller,
C.E. Shaw,Mutations in FUS, anRNAprocessing protein, cause familial amyotrophic
lateral sclerosis type 6, Science 323 (2009) 1208–1211.
[114] A. Crozat, P. Aman, N. Mandahl, D. Ron, Fusion of CHOP to a novel RNA-binding
protein in human myxoid liposarcoma, Nature 363 (1993) 640–644.
[115] T.H. Rabbitts, A. Forster, R. Larson, P. Nathan, Fusion of the dominant negative
transcription regulator CHOP with a novel gene FUS by translocation t(12;16)
in malignant liposarcoma, Nat. Genet. 4 (1993) 175–180.
[116] D. Dormann, C. Haass, TDP-43 and FUS: a nuclear affair, Trends Neurosci. 34
(2011) 339–348.
[117] S. Da Cruz, D.W. Cleveland, Understanding the role of TDP-43 and FUS/TLS in ALS
and beyond, Curr. Opin. Neurobiol. 21 (2011) 904–919.
[118] D.A. Bosco, N. Lemay, H.K. Ko, H. Zhou, C. Burke, T.J. Kwiatkowski Jr., P. Sapp, D.
McKenna-Yasek, R.H. Brown Jr., L.J. Hayward, Mutant FUS proteins that cause
amyotrophic lateral sclerosis incorporate into stress granules, Hum. Mol.
Genet. 19 (2010) 4160–4175.
[119] D. Dormann, R. Rodde, D. Edbauer, E. Bentmann, I. Fischer, A. Hruscha, M.E. Than,
I.R. Mackenzie, A. Capell, B. Schmid, M. Neumann, C. Haass, ALS-associated fused
in sarcoma (FUS) mutations disrupt transportin-mediated nuclear import,
EMBO J. 29 (2010) 2841–2857.
[120] J. Gal, J. Zhang, D.M. Kwinter , J. Zhai, H. Jia, J. Jia, H. Zhu, Nuclear localization
sequence of FUS and induction of stress granules by ALS mutants, Neurobiol.
Aging 32 (2011) 2323.e27–2323.e40.
[121] H. Doi, K. Okamura, P.O. Bauer, Y. Furukawa, H. Shimizu, M. Kurosawa, Y.
Machida, H. Miyazaki, K. Mitsui, Y. Kuroiwa, N. Nukina, RNA-binding protein
TLS is a major nuclear aggregate-interacting protein in huntingtin exon 1 with
expanded polyglutamine-expressing cells, J. Biol. Chem. 283 (2008) 6489–6500.
[122] Z. Sun, Z. Diaz, X. Fang, M.P. Hart, A. Chesi, J. Shorter, A.D. Gitler, Molecular
determinants and genetic modiﬁers of aggregation and toxicity for the ALS
disease protein FUS/TLS, PLoS Biol. 9 (2011) e1000614.
[123] D. Baumer, D. Hilton, S.M. Paine, M.R. Turner, J. Lowe, K. Talbot, O. Ansorge,
Juvenile ALS with basophilic inclusions is a FUS proteinopathy with FUS
mutations, Neurology 75 (2010) 611–618.
[124] E.J. Huang, J. Zhang, F. Geser, J.Q. Trojanowski, J.B. Strober, D.W. Dickson, R.H.
Brown Jr., B.E. Shapiro, C. Lomen-Hoerth, Extensive FUS-immunoreactive
pathology in juvenile amyotrophic lateral sclerosis with basophilic inclusions,
Brain Pathol. 20 (2010) 1069–1076.
[125] D. Dormann, T. Madl, C.F. Valori, E. Bentmann, S. Tahirovic, C. Abou-Ajram, E.
Kremmer, O. Ansorge, I.R. Mackenzie, M. Neumann, C. Haass, Arginine methyla-
tion next to the PY-NLS modulates transportin binding and nuclear import of
FUS, EMBO J. 31 (2012) 4258–4275.
[126] T.W. Han, M. Kato, S. Xie, L.C. Wu, H. Mirzaei, J. Pei, M. Chen, Y. Xie, J. Allen, G.
Xiao, S.L. McKnight, Cell-free formation of RNA granules: bound RNAs identify
features and components of cellular assemblies, Cell 149 (2012) 768–779.
[127] M. Kato, T.W. Han, S. Xie, K. Shi, X. Du, L.C. Wu, H. Mirzaei, E.J. Goldsmith, J.
Longgood, J. Pei, N.V. Grishin, D.E. Frantz, J.W. Schneider, S. Chen, L. Li, M.R.
Sawaya, D. Eisenberg, R. Tycko, S.L. McKnight, Cell-free formation of RNA granules:
low complexity sequence domains form dynamic ﬁbers within hydrogels, Cell 149
(2012) 753–767.
[128] O.D. King, A.D. Gitler, J. Shorter, The tip of the iceberg: RNA-binding proteins
with prion-like domains in neurodegenerative disease, Brain Res. 1462 (2012)
61–80.
